Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

Boston Biomedical Associates helps AtriCure's Synergy Ablation System win a Recommendation from FDA Expert Advisors

October 28, 2011 7:39 am | News | Comments

NORTHBOROUGH, Mass.--(BUSINESS WIRE)--Boston Biomedical Associates today announced that AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems and devices for the exclusion of the left atrial appendage, received a vote of approval support...

Avinger Debuts Kittycat 2 Catheter and Juicebox in US and EU Markets, Two Innovative Tools for the Treatment of Peripheral Artery Disease (PAD)

October 27, 2011 11:57 am | News | Comments

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for treating patients with Peripheral Artery Disease (PAD), announces today the release of two new products, Kittycat 2, a smaller more refined ultimate support catheter, and Juicebox...

Medtronic Starts Landmark Study of Hypertension Treatment

October 27, 2011 11:36 am | News | Comments

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic Inc. (NYSE: MDT) announced today the start of SYMPLICITY HTN-3, the company's U.S. clinical trial of the Symplicity® Renal Denervation System™ for treatment-resistant hypertension. The first patient in this landmark study was enrolled at the Prairie Heart Institute at St. John's Hospital in Springfield, Ill.


Reused pacemakers safe option in poor countries

October 27, 2011 6:09 am | News | Comments

(Reuters) - Recycled pacemakers donated from U.S. funeral homes could offer a safe way to get the heart devices to people in the developing world who otherwise might not be able to afford them, a U.S. study said. An estimated 1 million to 2 million people around the world die...

Oklahoma Pastor with Total Artificial Heart Marks 1 Year of Life at Home with Freedom Portable Driver

October 27, 2011 5:56 am | News | Comments

Tucson AZ USA -- Medical E-Mail Newsâ„¢ / Oct 26 2011 -- SynCardia Systems, Inc., manufacturer of the world's only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that Oklahoma pastor Troy Golden has surpassed one year of life

Medtronic heart device has safety issues: FDA staff

October 25, 2011 11:28 am | News | Comments

(Reuters) - U.S. reviewers said a Medtronic Inc device was effective for treating a common heart rhythm disorder, but they raised concerns about its safety. Medtronic's Cardiac Ablation System is designed to treat persistent atrial fibrillation...

'Extreme EVAR and TEVAR' a Hot Topic at the International Symposium on Endovascular Therapy (ISET) 2012

October 25, 2011 7:27 am | News | Comments

MIAMI BEACH, Fla., Oct. 25, 2011 -- Endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR) take center stage at the upcoming 24th Annual International Symposium on Endovascular Therapy (ISET), which brings together...

AtriCure heart device safe, with caveats: FDA staff

October 25, 2011 6:23 am | News | Comments

(Reuters) - AtriCure Inc's Synergy Ablation System heart-rhythm device is safe and effective, but its trial size and design raise some concerns, U.S. medical device reviewers said.


Neurosurgical and Neurovascular Device Market to Grow at Six Percent Per Year

October 25, 2011 6:01 am | News | Comments

TORONTO--(BUSINESS WIRE)--According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the market for the specialized devices used for neurosurgical and neurovascular treatments will grow to $240 million by 2016...

Cook Medical's Zilver PTX Drug-Eluting Stent Technology Receives Unanimous Recommendation from FDA Advisory Committee

October 14, 2011 5:38 am | News | Comments

The Zilver® PTX® Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the FDA's Circulatory System Devices Panel of the Medical Devices Advisory Committee...

Acetylon starts multiple myeloma treatment trial

September 23, 2011 8:33 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Acetylon Pharmaceuticals Inc. of Boston has begun a Phase 1-2a clinical trial of its multiple myeloma treatment, ACY-1215, just on the heels of the start of a patient study by the Multiple Myeloma Research Foundation.

NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis

September 23, 2011 8:32 am | by Bio-Medicine.Org | News | Comments

LAWRENCE, Mass., Sept. 23, 2011 /- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today commented on the just-released findings of an NIH sponsored study which shows that event rates, including mortality, were significantly higher for...

Personalized multiple myeloma study of 1,000 patients starts

September 22, 2011 8:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

The Multiple Myeloma Research Foundation said it has enrolled the first person in a 1,000-patient study aimed at discovering variations of the incurable blood cancer.


Cardica Achieves Milestone Under Century Distribution Agreement

September 22, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

REDWOOD CITY, Calif., Sept. 22, 2011 /- Cardica, Inc. (Nasdaq: CRDC ) today announced that it has achieved the first MicroCutter™ milestone under its distribution agreement and loan commitment with Century Medical, allowing Cardica to draw the first $2 million of an up to $4...

Sanovas CEO Larry Gerrans Featured Speaker at AdvaMed 2011

September 22, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

SAUSALITO, Calif., Sept. 22, 2011 /- Sanovas Inc. , a leading developer of minimally invasive technologies for the diagnosis and treatment of pulmonary disease and lung cancer, today announced that CEO and co-founder Larry Gerrans will speak at AdvaMed 2011, the industry's premier...

Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference

September 21, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Sept. 21, 2011 /- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that the company is scheduled to present at the Sixth Annual JMP Securities Healthcare Conference on Tuesday, September 27, 2011, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at The St....

At Home Healthcare Expands Telehealth Program With Cardiocom® Telehealth Technology

September 21, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

TYLER, Texas, Sept. 21, 2011 /- At Home Healthcare, a leading provider of home care announced it has entered into a business relationship with Cardiocom to provide advanced home telehealth technology to patients with chronic illness. Cardiocom®, Experts in Telehealth(SM), is a world...

Quantum Materials Corp and Nanoaxis Announce Technology Alliance

September 20, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

TEMPE, Ariz., Sept. 20, 2011 /- Quantum Materials Corporation ( ) (Pink Sheets: QTMM ) Quantum Materials Corp. and Nanoaxis, LLC announce the formation of a technology alliance combining Quantum Materials tetrapod quantum dot mass production technology with...

Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society

September 20, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

EMERYVILLE, Calif., Sept. 20, 2011 /- Bionovo, Inc. (NASDAQ: BNVI ), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that Dr. Mary Tagliaferri, President and Chief Medical Officer of...

MAQUET Cardiovascular Receives FDA 510(k) Clearance and CE Mark for Its New SENSATION PLUSâ„¢ Intra-Aortic Balloon Catheter

September 20, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

MAHWAH, N.J., Sept. 20, 2011 /- MAQUET Cardiovascular, a leading provider of cardiovascular technologies, announced today that it has received both 510(k) clearance from the U.S. Food & Drug Administration (FDA) and CE mark approval from the British Standards Institution (BSi) for its...

Thoratec Presentation at Lazard Capital Markets Circulatory Assist Device Day to be Webcast

September 20, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

PLEASANTON, Calif., Sept. 20, 2011 /- Thoratec Corporation (NASDAQ: THOR ), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Lazard Capital Markets 3rd Annual Circulatory...

Watson Pharmaceuticals Announces Approval of Amphastar's Generic LOVENOX(R)

September 20, 2011 12:33 am | by Bio-Medicine.Org | News | Comments

PARSIPPANY, N.J., Sept. 19, 2011 /- Watson Pharmaceuticals, Inc. (NYSE: WPI ) today announced that Amphastar Pharmaceuticals, Inc., has received U.S. Food and Drug Administration ("FDA") approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the...

HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day

September 19, 2011 1:33 pm | by Bio-Medicine.Org | News | Comments

FRAMINGHAM, Mass. and SYDNEY, Sept. 19, 2011 /- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug...

South and Central America Cardiovascular Devices Market Outlook to 2017

September 19, 2011 9:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Sept. 19, 2011 /- announces that a new market research report is available in its catalogue: South and Central America Cardiovascular Devices Market Outlook to 2017 ...

Studying Fluid Overflow in Patients With Devices

September 19, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

BOSTON, Sept. 19, 2011 /- The 15th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature a session entitled "Late Breaking Trials," which will highlight recent studies relating to heart failure. Dr. D.J. van Veldhuisen, from The UMC Groningen, The...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.